Fabricated trials distort guidelines

If a substantial share of clinical trials are fabricated or fatally flawed, then clinical guidelines, drug approvals, and patient-care decisions can be systematically biased because they rest on corrupted evidence. Fixing this requires routine provenance checks, mandatory raw-data access, and forensic-statistical screening before evidence is pooled into practice-changing recommendations. — This reframes research-integrity concerns as an immediate patient-safety and policy problem — not just an academic one — forcing regulators, guideline committees, and hospitals to demand data provenance and validation.